<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37720209</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registry.</ArticleTitle><Pagination><StartPage>1227403</StartPage><MedlinePgn>1227403</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1227403</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1227403</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Infection is a leading cause of death in patients with systemic lupus erythematosus (SLE). Alt hough hydroxychloroquine (HCQ) has been reported to inhibit infection, evidence from Asian populations remains insufficient. We investigated this effect in Japanese SLE patients.</AbstractText><AbstractText Label="METHODS">Data from the Lupus Registry of Nationwide Institutions were used in this study. The patients were &#x2265;20 years old and met the American College of Rheumatology (ACR) classification criteria revised in 1997. We defined "severe infections" as those requiring hospitalization. We analyzed the HCQ's effect on infection suppression using a generalized estimating equation (GEE) logistic regression model as the primary endpoint and performed a survival analysis for the duration until the first severe infection.</AbstractText><AbstractText Label="RESULTS">Data from 925 patients were used (median age, 45 [interquartile range 35-57] years; female, 88.1%). GEE analysis revealed that severe infections were significantly associated with glucocorticoid dose (odds ratio [OR] 1.968 [95% confidence interval, 1.379-2.810], <i>p</i>&lt;0.001), immunosuppressants (OR 1.561 [1.025-2.380], <i>p</i>=0.038), and baseline age (OR 1.043 [1.027-1.060], <i>p</i>&lt;0.001). HCQ tended to suppress severe infections, although not significantly (OR 0.590 [0.329-1.058], <i>p</i>=0.077). Survival time analysis revealed a lower incidence of severe infections in the HCQ group than in the non-HCQ group (<i>p</i>&lt;0.001). In a Cox proportional hazards model, baseline age (hazard ratio [HR] 1.029 [1.009-1.050], <i>p</i>=0.005) and HCQ (HR 0.322 [0.142-0.728], <i>p</i>=0.006) were significantly related to incidence.</AbstractText><AbstractText Label="CONCLUSION">HCQ may help extend the time until the occurrence of infection complications and tends to decrease infection rates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Hidekawa, Yoshimi, Saigusa, Tamura, Kojitani, Suzuki, Sakurai, Yoshioka, Sugiyama-Kawahara, Kunishita, Kishimoto, Higashitani, Sato, Komiya, Nagai, Hamada, Maeda, Tsuchida, Hirahara, Soejima, Takase-Minegishi, Kirino, Yajima, Sada, Miyawaki, Ichinose, Ohno, Kajiyama, Sato, Shimojima, Fujiwara and Nakajima.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hidekawa</LastName><ForeName>Chiharu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimi</LastName><ForeName>Ryusuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saigusa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojitani</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurai</LastName><ForeName>Natsuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshioka</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama-Kawahara</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunishita</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Daiga</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashitani</LastName><ForeName>Kana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yuichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komiya</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Hideto</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Ayaka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuchida</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirahara</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soejima</LastName><ForeName>Yutaro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takase-Minegishi</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirino</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yajima</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sada</LastName><ForeName>Ken-Ei</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyawaki</LastName><ForeName>Yoshia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichinose</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajiyama</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Morohongo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shuzo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimojima</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>Michio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asian</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">multicenter registry</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>KS received a speaker&#x2019;s fee from GlaxoSmithKline PLC and research grants from Pfizer Inc. YKi received a speaker&#x2019;s fee from Amgen and Novartis and research funding from Nippon Shinyaku. RY received a speaker&#x2019;s fee from GlaxoSmithKline PLC, AstraZeneca PLC, and Sanofi S.A. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>4</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37720209</ArticleId><ArticleId IdType="pmc">PMC10504661</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1227403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. The history of lupus throughout the ages. J Am Acad Dermatol (2022) 87(6):1361&#x2013;9. doi:&#xa0;10.1016/j.jaad.2020.04.150</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.04.150</ArticleId><ArticleId IdType="pubmed">32380218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Wang F, Pan W, Liu L, Wu M, Hu H, et al. . Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatol (Oxford) (2021) 60(4):1774&#x2013;83. doi:&#xa0;10.1093/rheumatology/keaa485</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa485</ArticleId><ArticleId IdType="pubmed">33099642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Vizcaya A, Isenberg D. Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. Lupus (2021) 30(5):702&#x2013;6. doi:&#xa0;10.1177/0961203320988607</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320988607</ArticleId><ArticleId IdType="pubmed">33472522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sis&#xf3; A, Ramos-Casals M, Bov&#xe9; A, Brito-Zer&#xf3;n P, Soria N, Mu&#xf1;oz S, et al. . Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus (2008) 17(4):281&#x2013;8. doi:&#xa0;10.1177/0961203307086503</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307086503</ArticleId><ArticleId IdType="pubmed">18413408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinjo SK, Bonf&#xe1; E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. . Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum (2010) 62(3):855&#x2013;62. doi:&#xa0;10.1002/art.27300</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27300</ArticleId><ArticleId IdType="pubmed">20131238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, McGwin G, Jr., Danila MI, Zhang J, Bastian HM, et al. . Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 61(6):830&#x2013;9. doi:&#xa0;10.1002/art.24538</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24538</ArticleId><ArticleId IdType="pmc">PMC2898742</ArticleId><ArticleId IdType="pubmed">19479701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis (2019) 78(6):736&#x2013;45. doi:&#xa0;10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther (2009) 11(4):R109. doi:&#xa0;10.1186/ar2764</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2764</ArticleId><ArticleId IdType="pmc">PMC2745791</ArticleId><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfa;a-Figueroa &#xcd;, L&#xf3;pez-Longo J, Galindo-Izquierdo M, Calvo-Al&#xe9;n J, Del Campo V, Oliv&#xe9;-Marqu&#xe9;s A, et al. . Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum (2017) 47(1):38&#x2013;45. doi:&#xa0;10.1016/j.semarthrit.2017.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.01.010</ArticleId><ArticleId IdType="pubmed">28259425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Echavarri C, Capdevila O, Espinosa G, Su&#xe1;rez S, Mar&#xed;n-Ballv&#xe9; A, Gonz&#xe1;lez-Le&#xf3;n R, et al. . Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus (2018) 27(14):2253&#x2013;61. doi:&#xa0;10.1177/0961203318811598</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318811598</ArticleId><ArticleId IdType="pubmed">30451641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo KJ, Chen HH, Chen YM, Lin CH, Chen DY, Lai CM, et al. . Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. BMC Infect Dis (2020) 20(1):112. doi:&#xa0;10.1186/s12879-020-4826-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-4826-1</ArticleId><ArticleId IdType="pmc">PMC7011312</ArticleId><ArticleId IdType="pubmed">32041539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sada KE, Katayama Y, Asano Y, Hayashi K, Miyawaki Y, Ohashi K, et al. . Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study. Lupus Sci Med (2022) 9:e000772. doi:&#xa0;10.1136/lupus-2022-000772</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000772</ArticleId><ArticleId IdType="pmc">PMC9516281</ArticleId><ArticleId IdType="pubmed">36167483</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Ishikawa Y, Kita Y, Yajima N, Inoue E, Sada KE, et al. . Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study. Arthritis Res Ther (2022) 24(1):179. doi:&#xa0;10.1186/s13075-022-02869-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02869-9</ArticleId><ArticleId IdType="pmc">PMC9330647</ArticleId><ArticleId IdType="pubmed">35902976</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyawaki Y, Shimizu S, Ogawa Y, Sada KE, Katayama Y, Asano Y, et al. . Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study. Arthritis Res Ther (2021) 23(1):79. doi:&#xa0;10.1186/s13075-021-02466-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02466-2</ArticleId><ArticleId IdType="pmc">PMC7944592</ArticleId><ArticleId IdType="pubmed">33691746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 40(9):1725. doi:&#xa0;10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. . Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 54(8):2550&#x2013;7. doi:&#xa0;10.1002/art.21955</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21955</ArticleId><ArticleId IdType="pubmed">16868977</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SJ, Choi H, Lee HS, Han SH, Chin BS, Baek JH, et al. . Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis (2009) 41(4):268&#x2013;74. doi:&#xa0;10.1080/00365540902744741</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540902744741</ArticleId><ArticleId IdType="pubmed">19172435</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard JF, Rossides M, Gunnarsson I, Svenungsson E, Arkema EV. Infection hospitalisation in systemic lupus in Sweden. Lupus Sci Med (2021) 8:e000510. doi:&#xa0;10.1136/lupus-2021-000510</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000510</ArticleId><ArticleId IdType="pmc">PMC8444249</ArticleId><ArticleId IdType="pubmed">34526357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatol (Oxford) (2021) 60(1):207&#x2013;16. doi:&#xa0;10.1093/rheumatology/keaa267</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa267</ArticleId><ArticleId IdType="pmc">PMC8312724</ArticleId><ArticleId IdType="pubmed">32653901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, Wojdyla D, Pons-Estel GJ, Quintana R, et al. . Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus (2019) 28(9):1101&#x2013;10. doi:&#xa0;10.1177/0961203319860579</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319860579</ArticleId><ArticleId IdType="pubmed">31291843</ArticleId></ArticleIdList></Reference><Reference><Citation>Prata AR, Lu&#xed;s M, Assun&#xe7;&#xe3;o H, da Silva JAP, In&#xea;s LS. Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clin Rheumatol (2022) 41(4):1069&#x2013;78. doi:&#xa0;10.1007/s10067-021-05988-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05988-x</ArticleId><ArticleId IdType="pubmed">34782940</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med (2016) 14(1):137. doi:&#xa0;10.1186/s12916-016-0673-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0673-8</ArticleId><ArticleId IdType="pmc">PMC5022202</ArticleId><ArticleId IdType="pubmed">27623861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Shen LJ, Hsu PN, Shen CY, Hall SA, Hsiao FY. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol (2018) 45(1):83&#x2013;9. doi:&#xa0;10.3899/jrheum.160214</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.160214</ArticleId><ArticleId IdType="pubmed">29142034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. . Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis (2015) 74(9):1706&#x2013;13. doi:&#xa0;10.1136/annrheumdis-2013-205171</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Hydroxychloroquine improves the disease activity and allows the reduction of the corticosteroid dose regardless of background treatment in Japanese patients with systemic lupus erythematosus. Intern Med (2019) 58(9):1257&#x2013;62. doi:&#xa0;10.2169/internalmedicine.1999-18</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.1999-18</ArticleId><ArticleId IdType="pmc">PMC6543229</ArticleId><ArticleId IdType="pubmed">30626831</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier E, D&#xf6;rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol (2020) 16(3):155&#x2013;66. doi:&#xa0;10.1038/s41584-020-0372-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0372-x</ArticleId><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal P, Goyal A, Cusick At, Lahan S, Dhaliwal HS, Bhyan P, et al. . Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med (2021) 53(1):117&#x2013;34. doi:&#xa0;10.1080/07853890.2020.1839959</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1839959</ArticleId><ArticleId IdType="pmc">PMC7880079</ArticleId><ArticleId IdType="pubmed">33095083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents (2007) 30(4):297&#x2013;308. doi:&#xa0;10.1016/j.ijantimicag.2007.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2007.05.015</ArticleId><ArticleId IdType="pmc">PMC7126847</ArticleId><ArticleId IdType="pubmed">17629679</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriet SS, Jans J, Simonetti E, Kwon-Chung KJ, Rijs AJ, Hermans PW, et al. . Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease. J Infect Dis (2013) 207(12):1932&#x2013;9. doi:&#xa0;10.1093/infdis/jit103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit103</ArticleId><ArticleId IdType="pubmed">23482646</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis (2003) 3(11):722&#x2013;7. doi:&#xa0;10.1016/s1473-3099(03)00806-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(03)00806-5</ArticleId><ArticleId IdType="pmc">PMC7128816</ArticleId><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents (2020) 55(5):105960. doi:&#xa0;10.1016/j.ijantimicag.2020.105960</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105960</ArticleId><ArticleId IdType="pmc">PMC7128678</ArticleId><ArticleId IdType="pubmed">32251731</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez JC, Davido B, Moine P, Etting I, Annane D, Larabi IA, et al. . Population pharmacokinetics of hydroxychloroquine and 3 metabolites in COVID-19 patients and pharmacokinetic/pharmacodynamic application. Pharm (Basel) (2022) 15:256. doi:&#xa0;10.3390/ph15020256</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15020256</ArticleId><ArticleId IdType="pmc">PMC8877570</ArticleId><ArticleId IdType="pubmed">35215368</ArticleId></ArticleIdList></Reference><Reference><Citation>Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol (1989) 27(6):771&#x2013;9. doi:&#xa0;10.1111/j.1365-2125.1989.tb03439.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1989.tb03439.x</ArticleId><ArticleId IdType="pmc">PMC1379804</ArticleId><ArticleId IdType="pubmed">2757893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, et al. . Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: A multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol (2017) 69(4):791&#x2013;9. doi:&#xa0;10.1002/art.40018</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40018</ArticleId><ArticleId IdType="pubmed">27992698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Franc&#xe8;s C, Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol (2017) 177(1):188&#x2013;96. doi:&#xa0;10.1111/bjd.15312</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.15312</ArticleId><ArticleId IdType="pubmed">28112801</ArticleId></ArticleIdList></Reference><Reference><Citation>
[Internet] ISAoJ . Immigration Control 2017 (2017). Available at: https://www.moj.go.jp/isa/content/930003500.pdf (Accessed 26 December 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>